{"url":"https://newsforagent.com/news/2026-10-21/xcellerant-ventures-geneticure-1m-investment","markdown_url":"https://newsforagent.com/news/2026-10-21/xcellerant-ventures-geneticure-1m-investment.md","title":"Xcellerant Ventures Backs Geneticure With $1 million Fund I","headline":"Xcellerant Ventures Invests $1 Million in Geneticure to Scale Renal Denervation Test","description":"Xcellerant Ventures invested $1 million in Geneticure to scale its renal denervation responder test and open an Arizona clinical lab ahead of a planned Series A.","section":"Funding","published_at":"2026-10-21T12:24:28+00:00","modified_at":"2026-10-21T12:24:28+00:00","author":"News Desk","key_takeaways":["Xcellerant Ventures announced a $1 million Fund I investment in Geneticure on October 21, 2026.","Geneticure's cheek swab test analyzes four physiologic pathways to predict response to renal denervation, an FDA-approved procedure with 35 million eligible U.S. patients.","Geneticure will use the capital to advance clinical validation, refine its reimbursement strategy and build commercial readiness ahead of a planned Series A round."],"companies":[{"name":"Xcellerant Ventures","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0005bit/xcellerant-ventures","website":"https://www.xcellerantventures.com"},{"name":"Geneticure","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0003i9j/geneticure","website":"https://geneticure.com"}],"source":{"publisher":"PR Newswire","title":"Xcellerant Ventures Invests $1M in Geneticure to Advance Precision Medicine and Expand Arizona's Biotech Hub","url":"https://www.prnewswire.com/news-releases/xcellerant-ventures-invests-1m-in-geneticure-to-advance-precision-medicine-and-expand-arizonas-biotech-hub-302912338.html"},"other_sources":[{"publisher":"pegn","url":"https://pipelinevalor.globo.com/startups/noticia/alice-levanta-us-40-milhoes-em-serie-d-com-braco-do-banco-mundial.ghtml"},{"publisher":"Wamda.com","url":"http://wamda.com/2026/10/uae-healthtech-vitalls-secures-1-5-million-investment-est-growmore"}],"tags":["Funding","Xcellerant Ventures","Geneticure"],"body_markdown":"[Xcellerant Ventures](https://akta.pro/company-profiles/0005bit/xcellerant-ventures) announced a $1 million Fund I investment in [Geneticure](https://akta.pro/company-profiles/0003i9j/geneticure), a precision medicine company developing tests that predict patient response to hypertension treatments, on October 21, 2026. [PR Newswire](https://www.prnewswire.com/news-releases/xcellerant-ventures-invests-1m-in-geneticure-to-advance-precision-medicine-and-expand-arizonas-biotech-hub-302912338.html) carried the announcement. The capital will accelerate Geneticure's commercial scaling and support a new clinical laboratory in Arizona.\n\n## Geneticure's Renal Denervation Test and Arizona Lab\n\nGeneticure uses a non-invasive cheek swab test to analyze four physiologic pathways, predicting whether a patient with resistant hypertension will respond to renal denervation, an FDA-approved procedure with 35 million eligible U.S. patients. More than 10 million of those patients may see no benefit, and the company's responder score is intended to give physicians confidence in patient selection, lower payer costs and drive clinical adoption.\n\n\"Renal denervation is a game-changer, but identifying the right candidates has been the critical missing link,\" said Mike Shufeldt, General Partner at Xcellerant Ventures. \"Geneticure delivers that clarity. We are thrilled to back a team with deep Arizona roots as they build a state-of-the-art laboratory here, bringing healthtech innovation and biotech jobs to our local economy.\"\n\n\"Increasing our presence in Arizona puts Geneticure close to the clinical partners and talent we need to scale,\" said Scott Snyder, CEO of Geneticure. \"Xcellerant brings more than capital, and we are excited to work with their team as we bring renal denervation responder testing to physicians and patients.\"\n\nGeneticure will use the funding to advance clinical validation, refine its reimbursement strategy and build commercial readiness ahead of a planned Series A round. Alongside its renal denervation platform, Geneticure holds four U.S. patents and offers a commercial hypertension test guiding daily medication selection.\n\n## Xcellerant Ventures' Fund and Portfolio Record\n\nXcellerant Ventures is a Phoenix-based early-stage venture capital firm founded in 2023 that invests in HealthTech, MedTech and BioTech startups through XVC Fund 1 and the SEC-registered Jetstream interval fund, according to akta.pro [company records](https://akta.pro/company-data). The firm has invested in over 10 portfolio companies including DeepLook Medical, CRISPR QC, Lenoss Medical, Nanodropper, AdviNOW Medical, Mindset Medical, Wave Health and TruLite Health. In March 2026 it lowered the Jetstream Venture Fund minimum initial investment from $20,000 to $5,000, and in April 2026 it completed Jetstream's first dedicated AI investment in Hill Research and an investment in Surf Therapeutics.\n\n## Healthtech Rounds From Alice and Vitalls\n\nAlice, a Brazilian healthtech, raised $40 million in a Series D led by the World Bank's IFC, with participation from DEG and FinnFund, [pegn](https://pipelinevalor.globo.com/startups/noticia/alice-levanta-us-40-milhoes-em-serie-d-com-braco-do-banco-mundial.ghtml) reported on October 19, 2026. UAE healthtech Vitalls secured a $1.5 million seed investment from Singapore-based EST Growmore, with an option for a further $1 million, [Wamda.com](http://wamda.com/2026/10/uae-healthtech-vitalls-secures-1-5-million-investment-est-growmore) reported on October 19, 2026.\n\n## Geneticure's Planned Series A\n\nGeneticure's planned Series A round follows the $1 million Fund I investment, the company said. Xcellerant's institutional Fund I is now closed, while individual investors can access Xcellerant's early-stage healthcare pipeline through Jetstream Venture Fund.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}